ProQR Therapeutics Competitors and Similar CompaniesClear all
ProQR Therapeutics's competitors and similar companies include Graphite Bio, Asklepios BioPharmaceutical, Cell Therapies and Precigen.
 ProQR Therapeutics ProQR Therapeutics is a company that develops RNA therapies designed for patients suffering from genetic rare diseases. |  Graphite Bio Graphite Bio is a gene-editing company focused on the development of therapies for patients suffering from life-threatening genetic diseases. |  Asklepios BioPharmaceutical Asklepios BioPharmaceutical is engaged in the development and delivery of novel protein. |  Cell Therapies Cell Therapies is a manufacturer of cell therapies, gene therapies, cellular immunotherapies, and regenerative medicine products. |  Precigen Precigen (formerly known as Intrexon) is a biopharmaceutical company developing gene and cellular therapies for immuno-oncology, autoimmune, and infectious diseases. | |
Founding Date | Founding Date 2012 | Founding Date 2017 | Founding Date 2001 | Founding Date 2003 | Founding Date 1998 |
Type | Type Public | Type Public | Type Private | Type Private | Type Public |
Tags | |||||
Locations | Locations Leiden, NL HQ Cambridge, US | Locations South San Francisco, US HQ | Locations Chapel Hill, US HQ Roslin, GB | Locations Melbourne, AU HQ | Locations Germantown, US HQ Gent, BE Sioux Center, US |
Employees | Employees 166 | Employees 27 | Employees 5172% increase | Employees 733% decrease | Employees 601 |
Valuation ($) | Valuation ($) 281.8 m | Valuation ($) 185.2 m | Valuation ($) N/A | Valuation ($) N/A | Valuation ($) 246.6 m |
Financial | |||||
Revenue (est.) | Revenue (est.) €15.9m (FY, 2025) | Revenue (est.) $19.1m (FY, 2025) | Revenue (est.) N/A | Revenue (est.) N/A | Revenue (est.) $9.7m (FY, 2025) |
Cost of goods | Cost of goods N/A | Cost of goods $418k (FY, 2025) | Cost of goods N/A | Cost of goods N/A | Cost of goods N/A |
Gross profit | Gross profit €16.3m (FY, 2025) | Gross profit $18.7m (FY, 2025) | Gross profit N/A | Gross profit N/A | Gross profit N/A |
Net income | Net income (€42.2m) (FY, 2025) | Net income ($82.1m) (FY, 2025) | Net income N/A | Net income N/A | Net income ($250.6m) (FY, 2025) |
Funding | |||||
Total funding raised | Total funding raised $ 57.8m | Total funding raised N/A | Total funding raised $ 235m | Total funding raised N/A | Total funding raised $ 379m |
For sources of this data, please see the company profile
View Company Profiles
Graphite Bio
HQ
South San Francisco, US
Employees
27
Graphite Bio is a gene-editing company focused on the development of therapies for patients suffering from life-threatening genetic diseases.
View companyAsklepios BioPharmaceutical
HQ
Chapel Hill, US
Employees
517↑ 2% increase
Asklepios BioPharmaceutical is engaged in the development and delivery of novel protein.
View companyCell Therapies
HQ
Melbourne, AU
Employees
73↓ 3% decrease
Cell Therapies is a manufacturer of cell therapies, gene therapies, cellular immunotherapies, and regenerative medicine products.
View companyPrecigen
HQ
Germantown, US
Employees
601
Precigen (formerly known as Intrexon) is a biopharmaceutical company developing gene and cellular therapies for immuno-oncology, autoimmune, and infectious diseases.
View company